A new paradigm in therapeutic development is emerging as Remepy, a pioneering startup, successfully completed a Phase IIa clinical trial…
Read More
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
Recent findings presented at the 26th International AIDS Conference have underscored a significant advancement in HIV treatment, with an investigational…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More
Remepy’s Hybridopa, a Pioneer in AI-Driven Hybrid Drugs, Demonstrates Significant Efficacy in Parkinson’s Phase IIa Trial
San Francisco, CA – May 2026 – Remepy, a burgeoning health technology startup at the vanguard of integrating pharmaceutical and…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
A new era in therapeutic innovation is dawning, marked by the successful Phase IIa clinical trial results for Hybridopa, an…
Read More
Researchers Unveil Fractional Fermi Seas as a New Critical Phase of Quantum Matter Beyond Conventional Equilibrium Models
The landscape of modern physics has been significantly expanded by a collaborative research effort demonstrating that an exotic class of…
Read More
Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital, and industry converge at Campus Grand Parc.
The recent inauguration of THE HIVE at Campus Grand Parc in Paris marks a significant inflection point for Europe’s oncology…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
In a significant advancement for integrated medicine, Remepy, a pioneering startup, has announced successful Phase IIa clinical trial results for…
Read MoreYOU MAY HAVE MISSED
